Linkedin twitter facebook Contact Us

Agilis is focused on engineering first-in-class DNA-based therapeutics to improve the lives of patients affected by life-threatening or fatal rare diseases. Our initial program is focused on a therapy for patients with Friedreich’s ataxia.

Agilis is advancing biologically-based solutions that utilize engineered DNA, proteins, and cells to target the underlying disease with increased precision and control.